Mirati Therapeutics (NASDAQ:MRTX) had its price target raised by HC Wainwright from $17.00 to $21.00 in a research report sent to investors on Tuesday, January 9th, Marketbeat.com reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also recently weighed in on MRTX. Leerink Swann lifted their price target on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a market perform rating in a research note on Friday, September 15th. ValuEngine upgraded shares of Mirati Therapeutics from a strong sell rating to a sell rating in a research report on Friday, September 15th. Oppenheimer initiated coverage on shares of Mirati Therapeutics in a research report on Monday, September 18th. They set an outperform rating and a $18.00 price objective on the stock. Cann initiated coverage on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. They set an outperform rating on the stock. Finally, Citigroup restated a buy rating and set a $16.00 price objective (up from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. Mirati Therapeutics currently has an average rating of Buy and a consensus price target of $14.75.
Shares of Mirati Therapeutics (NASDAQ MRTX) opened at $24.75 on Tuesday. Mirati Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $25.20. The stock has a market cap of $668.09, a P/E ratio of -7.96 and a beta of 1.61.
In other Mirati Therapeutics news, major shareholder Venbio Select Advisor Llc bought 650,000 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jamie Christensen sold 7,499 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00. Following the completion of the sale, the senior vice president now owns 10,169 shares in the company, valued at $142,366. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,499 shares of company stock worth $628,464. 5.10% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of MRTX. Royce & Associates LP increased its holdings in shares of Mirati Therapeutics by 88.7% in the 2nd quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after buying an additional 118,063 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Mirati Therapeutics by 53.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock worth $728,000 after purchasing an additional 69,377 shares during the period. PDT Partners LLC purchased a new position in shares of Mirati Therapeutics during the 2nd quarter worth about $200,000. Goldman Sachs Group Inc. boosted its stake in shares of Mirati Therapeutics by 845.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 87,858 shares during the period. Finally, Susquehanna International Group LLP boosted its stake in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 16,030 shares during the period. Hedge funds and other institutional investors own 64.68% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was first posted by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://baseballnewssource.com/markets/mirati-therapeutics-mrtx-pt-raised-to-21-00/1820243.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.